Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative empagliflozin for renal and metabolic outcomes in cardiac surgery
NL-OMON52118Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin in acute kidney failure (AKF) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Plasma neutrophil gelatinase-associated lipocalin concentration on postoperative day 2. Started Mar 2022; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON52118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52118.